Clinical trial
A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT05218668 is registered in ClinicalTrials.gov with Woolsey Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- Woolsey Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- December 22, 2021
- Completion date
- January 31, 2029
- Enrollment
- 40 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.